Protea Vaccine Technologies signs an exclusive Research and License Option Agreement with GSK for Pneumococcal vaccine
Under the collaboration and option agreement, Protea and GSK will collaborate in executing an R&D plan funded by GSK on Protea's pneumococcal proteins, all of which are in pre-clinical development. In addition, GSK is acquiring an option to obtain an exclusive worldwide license to develop and commercialize vaccines based on Protea's proteins.
Under the terms of the agreement, Protea will receive R&D funding and an option fee in an aggregate amount of approximately 2.4 million Euro. Upon exercising the option, GSK would pay Protea an upfront license fee and subsequent milestone payments totaling approximately 17 million Euro. Protea also would be entitled to royalties on products commercialized by GSK.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.